- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07529873
Étude de phase II du Ficerafusp Alfa en association avec le Nivolumab chez des patients atteints d'un carcinome épidermoïde de la tête et du cou réfractaire au platine (N'FORCE)
Une étude de phase II du Ficerafusp Alfa (BCA 101) en association avec le Nivolumab chez des patients atteints d'un carcinome épidermoïde de la tête et du du cou réfractaire au platine, ayant progressé dans les 6 mois après un traitement multimodal pour une maladie localement avancée (BICARA)
This is a multicenter study comprising two phases: a run-in phase, including only patients receiving ficerafusp alfa and nivolumab, and a randomized phase, which corresponds to a randomized, open-label, phase II comparative study.
The primary objective is to compare the objective response rate (ORR) of patients with platinum refractory HNSCC with progressive disease within the 6 months after multimodal curative treatment treated with ficerafusp alfa (BCA 101) and nivolumab versus nivolumab alone.
There is a strong medical justification for combining ficerafusp alfa with nivolumab (anti-PD-1) to provide additional clinical benefit to patients with platinum-refractory HNSCC who are progressing within 6 months of multimodal treatment for locally advanced disease.
In the Run-in phase, patients will receive the following treatment regimens according to the study intervention plan:
Combination of Ficerafusp alfa + Nivolumab
- Ficerafusp alfa 1500 mg every week
- Nivolumab 240 mg every 2 weeks
In the randomized trial:
- ARM A Combination of Ficerafusp alfa + Nivolumab Ficerafusp alfa 1500 mg every week Nivolumab 240 mg every 2 weeks
- ARM B Nivolumab monotherapy Nivolumab 240 mg every 2 weeks
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Marceline EMGOUE
- Numéro de téléphone: 0033 02 42 06 02 56
- E-mail: reglementaire@gortec.fr
Lieux d'étude
-
-
-
Villejuif, France, 94805
- Recrutement
- Gustave Roussy
-
Contact:
- Caroline EVEN, Dr
- Numéro de téléphone: 0142116597
- E-mail: caroline.even@gustaveroussy.fr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patient or legally authorized representative, if applicable, has signed and dated informed consent form (ICF) indicating that the patient (or legally authorized representative, if applicable) has been informed of all the pertinent aspects of the study prior to enrollment and the patient must be willing to comply with all study procedures for the duration of the study.
- Patient is >18 years, ≤75 years of age on the day the ICF is signed.
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 (see Appendix 1).
- Histologically or cytologically confirmed squamous cell carcinoma of head and neck (HNSCC). Eligible primary tumor locations are oral cavity, larynx hypopharynx, or oropharynx (OPSCC).
- Local, regional or metastatic progression within 6 months after the last dose of platinum in a multimodal strategy for locally advanced stage, not amenable to salvage surgery in case of local or regional progression.
Specification regarding inclusion criterion no. 05 : Progression is not assessed as per RECIST. Any of the following will be considered as progression:
- A positive biopsy 3 months after the end of radiotherapy given with curative intent
- Appearance of any new lesion (e.g.: metastases or lymph nodes)
- Any increase in tumor size
- Any persisting tumor (confirmed with a biopsy) not amenable to salvage surgery
- For OPSCC patients, a pathological report determination of human papillomavirus (HPV) status by p16 expression must be p16 negative -Measurable tumor lesion(s) assessed by H&N-computed tomography scan (CT-scan) or magnetic resonance imaging (MRI), based on RECIST v 1.1 (see Appendix 3). Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated.
Exclusion Criteria:
- Primary tumor of nasopharyngeal, paranasal sinuses, nasal cavity or salivary gland, thyroid or parathyroid gland pathologies, skin, squamous cell carcinoma of unknown primary or non-squamous histologies (e.g., mucosal melanoma).
- Patients having received prior systemic treatment for metastatic or recurrent disease.
- Patients having received prior treatment with anti-EGFR antibody.
- Patients having received prior treatment with anti-TGF-β therapy.
- Patients having received prior therapy with anti-PD1, anti-PD-L1 (or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to registration/randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer defined as follows: Stage T1 up to T2a with a Gleason score ≤6 and prostatic specific antigen <10 ng/mL either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to registration/randomization. Other exceptions may be considered with the Sponsor's consultation. The time requirement for no malignancy for 2 years does not apply to the cancer for which a patient is enrolled in the study.
- Any of the following <6 months before starting study treatment: ST-elevation myocardial infarction, severe/unstable angina, uncontrolled cardiac ventricular arrythmia, coronary/peripheral artery bypass graft or stent, cerebrovascular accident/stroke less than 6 months prior to enrollment or NYHA Class III/IV congestive heart failure. Subjects with deep vein thrombosis who are hemodynamically stable can enroll if they are on a stable dose of anticoagulants for at least 3 months.
- Serious systemic infection (bacterial, viral, or fungal) within 4 weeks before first dose of study treatment, or active systemic infection requiring either hospitalization or parenteral anti-infective therapy within 2 weeks before first dose of study treatment.
- History of (non-infectious) pneumonitis/ interstitial lung disease or has current pneumonitis/ Interstitial lung disease.
- Active central nervous system (CNS) metastases or carcinomatous meningitis. Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded. Patients with a history of treated central nervous system metastases (by surgery or radiation therapy) may be eligible if central nervous system metastases have been stable for at least 4 weeks, i.e., without evidence of progression by repeat imaging and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
- History of uncontrolled seizures, CNS disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Ficerafusp + nivolumab
Combination of Ficerafusp alfa + Nivolumab
|
Ficerafusp alfais a bifunctional recombinant fusion protein consisting of a chimeric anti-EGFR mAb and human TGFβRII-ECD Nivolumab is a monoclonal antibody that binds to and blocks the programmed cell death 1 receptor. It is used to treat certain cancers. |
|
Comparateur actif: Nivolumab
Nivolumab monotherapy • Nivolumab 240 mg every 2 weeks |
Nivolumab is a monoclonal antibody that binds to and blocks the programmed cell death 1 receptor. It is used to treat certain cancers. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective response rate (ORR)
Délai: Through study completion, an average of 4 years
|
the objective response rate (ORR) which is defined as the proportion of patients with a confirmed best overall response (BOR) complete response (CR) or partial response (PR) as determined by the investigator according to RECIST criteria 1.1. |
Through study completion, an average of 4 years
|
Collaborateurs et enquêteurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Tumeurs de la tête et du cou
- Tumeurs, glandulaires et épithéliales
- Carcinome
- Carcinome épidermoïde
- Carcinome épidermoïde de la tête et du cou
- Acides aminés, peptides et protéines
- Protéines
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Nivolumab
Autres numéros d'identification d'étude
- GORTEC 2025-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The study will be conducted in Europe with GORTEC as sponsor. Pseudonymized participant data may be shared with the owner of the product ficerasup alfa.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .